165 related articles for article (PubMed ID: 35898161)
1. Successful treatment of metastatic fibrosarcomatous dermatofibrosarcoma protuberans with imatinib mesylate.
Kambayashi Y; Kasahara Y; Ohuchi K; Amagai R; Hashimoto A; Asano Y; Fujimura T
Dermatol Ther; 2022 Oct; 35(10):e15736. PubMed ID: 35898161
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
Rutkowski P; Klimczak A; Ługowska I; Jagielska B; Wągrodzki M; Dębiec-Rychter M; Pieńkowska-Grela B; Świtaj T
Eur J Surg Oncol; 2017 Jun; 43(6):1134-1141. PubMed ID: 28365129
[TBL] [Abstract][Full Text] [Related]
3. Dermatofibrosarcoma protuberans with fibrosarcomatous transformation: a case report.
Hrudka J; Charvát M; Grossmann P; Kinkor Z
Cesk Patol; 2020; 56(2):89-93. PubMed ID: 32493025
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP).
Stacchiotti S; Pantaleo MA; Negri T; Astolfi A; Tazzari M; Dagrada GP; Urbini M; Indio V; Maestro R; Gronchi A; Fiore M; Dei Tos AP; Conca E; Palassini E; Vincenzi B; Grosso F; Pilotti S; Castelli C; Casali PG
Clin Cancer Res; 2016 Feb; 22(4):837-46. PubMed ID: 26261104
[TBL] [Abstract][Full Text] [Related]
5. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.
Wang C; Luo Z; Chen J; Zheng B; Zhang R; Chen Y; Shi Y
Medicine (Baltimore); 2015 May; 94(17):e773. PubMed ID: 25929918
[TBL] [Abstract][Full Text] [Related]
6. Dermatofibrosarcoma protuberans: a clinicopathological, immunohistochemical, genetic (COL1A1-PDGFB), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors.
Llombart B; Monteagudo C; Sanmartín O; López-Guerrero JA; Serra-Guillén C; Poveda A; Jorda E; Fernandez-Serra A; Pellín A; Guillén C; Llombart-Bosch A
J Am Acad Dermatol; 2011 Sep; 65(3):564-575. PubMed ID: 21570152
[TBL] [Abstract][Full Text] [Related]
7. CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.
Eilers G; Czaplinski JT; Mayeda M; Bahri N; Tao D; Zhu M; Hornick JL; Lindeman NI; Sicinska E; Wagner AJ; Fletcher JA; Mariño-Enriquez A
Mol Cancer Ther; 2015 Jun; 14(6):1346-53. PubMed ID: 25852058
[TBL] [Abstract][Full Text] [Related]
8. Fibrosarcomatous ("high-grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance.
Mentzel T; Beham A; Katenkamp D; Dei Tos AP; Fletcher CD
Am J Surg Pathol; 1998 May; 22(5):576-87. PubMed ID: 9591728
[TBL] [Abstract][Full Text] [Related]
9. Novel TNC-PDGFD fusion in fibrosarcomatous dermatofibrosarcoma protuberans: a case report.
Chen Y; Shi YZ; Feng XH; Wang XT; He XL; Zhao M
Diagn Pathol; 2021 Jul; 16(1):63. PubMed ID: 34256767
[TBL] [Abstract][Full Text] [Related]
10. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report.
Lemm D; Muegge LO; Hoeffken K; Aklan T; Mentzel T; Thorwarth M; Schultze-Mosgau S
Oral Maxillofac Surg; 2008 Dec; 12(4):209-13. PubMed ID: 18751744
[TBL] [Abstract][Full Text] [Related]
11. PDGFB rearrangement in dermatofibrosarcoma protuberans: correlation with clinicopathologic characteristics and clinical implications.
Ha SY; Lee SE; Kwon MJ; Kim YJ; Lee EH; Seo J; Jang KT; Lee J; Choi YL
Hum Pathol; 2013 Jul; 44(7):1300-9. PubMed ID: 23347652
[TBL] [Abstract][Full Text] [Related]
12. Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans: A Systematic Review.
Navarrete-Dechent C; Mori S; Barker CA; Dickson MA; Nehal KS
JAMA Dermatol; 2019 Mar; 155(3):361-369. PubMed ID: 30601909
[TBL] [Abstract][Full Text] [Related]
13. Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment.
Tazzari M; Indio V; Vergani B; De Cecco L; Rini F; Negri T; Camisaschi C; Fiore M; Stacchiotti S; Dagrada GP; Casali PG; Gronchi A; Astolfi A; Pantaleo MA; Villa A; Lombardo C; Arienti F; Pilotti S; Rivoltini L; Castelli C
J Invest Dermatol; 2017 Feb; 137(2):484-493. PubMed ID: 27608549
[TBL] [Abstract][Full Text] [Related]
14. Dermatofibrosarcoma protuberans with fibrosarcomatous areas. Molecular abnormalities of the p53 pathway in fibrosarcomatous transformation of dermatofibrosarcoma protuberans.
Hisaoka M; Okamoto S; Morimitsu Y; Tsuji S; Hashimoto H
Virchows Arch; 1998 Oct; 433(4):323-9. PubMed ID: 9808434
[TBL] [Abstract][Full Text] [Related]
15. CD34 positivity in fibrosarcomas which arise in dermatofibrosarcoma protuberans.
Goldblum JR
Arch Pathol Lab Med; 1995 Mar; 119(3):238-41. PubMed ID: 7534057
[TBL] [Abstract][Full Text] [Related]
16. [Fibrosarcomatous dermatofibrosarcoma protuberans: a clinicopathological analysis of 12 cases].
Zhang J; Wu N; Xia C; Wei X; Shi QL; Zhou XJ; Ma J
Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):753-7. PubMed ID: 24447553
[TBL] [Abstract][Full Text] [Related]
17. Fine-needle aspiration of dermatofibrosarcoma protuberans metastasizing to hemithorax with superior vena cava compression: Case report and literature review.
Banach BS; Antic T; Bridge JA; Cipriani NA; Frye L; Krausz TN; Biernacka A
Diagn Cytopathol; 2019 Aug; 47(8):797-802. PubMed ID: 30919592
[TBL] [Abstract][Full Text] [Related]
18. Congenital dermatofibrosarcoma protuberans with fibrosarcomatous and myxoid change.
Gu W; Ogose A; Kawashima H; Umezu H; Kudo N; Hotta T; Endo N
J Clin Pathol; 2005 Sep; 58(9):984-6. PubMed ID: 16126884
[TBL] [Abstract][Full Text] [Related]
19. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR
Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598
[TBL] [Abstract][Full Text] [Related]
20. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.
Stacchiotti S; Pedeutour F; Negri T; Conca E; Marrari A; Palassini E; Collini P; Keslair F; Morosi C; Gronchi A; Pilotti S; Casali PG
Int J Cancer; 2011 Oct; 129(7):1761-72. PubMed ID: 21128251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
